|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,275.00 JPY | -2.61% |
|
-9.19% | +15.80% |
| 06-04 | Otsuka says kidney disease drug preserves function in late-stage study | RE |
| 05-29 | Merck Gets FDA Breakthrough Designation for Calderasib in NSCLC | DJ |
| Market Cap | 5,555B 34.66B 30.02B 27.54B 25.91B 48.26B 3,303B 49.02B 327B 127B 1,597B 130B 127B | P/E ratio 2026 * |
17.6x | P/E ratio 2027 * | 16.4x |
|---|---|---|---|---|---|
| Enterprise value | 5,093B 31.78B 27.52B 25.25B 23.76B 44.25B 3,028B 44.94B 300B 117B 1,464B 119B 117B | EV / Sales 2026 * |
1.96x | EV / Sales 2027 * | 1.85x |
| Free-Float |
81.44% | Yield 2026 * |
1.38% | Yield 2027 * | 1.48% |
Last Transcript: Otsuka Holdings Co., Ltd.
| 1 day | -2.61% | ||
| 1 week | -9.19% | ||
| Current month | -12.29% | ||
| 1 month | -6.51% | ||
| 3 months | +4.10% | ||
| 6 months | +11.44% | ||
| Current year | +15.80% |
| 1 week | 10,260 |  | 11,190 |
| 1 month | 10,260 | | 11,910 |
| Current year | 8,671 | | 11,910 |
| 1 year | 6,511 | | 11,910 |
| 3 years | 4,857 | | 11,910 |
| 5 years | 3,827 | | 11,910 |
| 10 years | 3,224 | | 11,910 |
| Manager | Title | Age | Since |
|---|---|---|---|
Makoto Inoue
CEO | Chief Executive Officer | 67 | 2024-12-31 |
Yuko Makino
DFI | Director of Finance/CFO | 64 | 2018-02-28 |
Masanori Udagawa
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Tatsuo Higuchi
BRD | Director/Board Member | 76 | 2008-07-07 |
Noriko Tojo
BRD | Director/Board Member | 62 | 2008-08-19 |
Yoshiro Matsuo
BRD | Director/Board Member | 65 | 2008-07-07 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.61% | -9.19% | +44.01% | +90.28% | 34.66B | |
| -0.55% | -0.61% | +4.99% | +80.80% | 45.04B | |
| -0.82% | -0.20% | -8.64% | +42.02% | 11.77B | |
| +1.66% | +2.53% | +13.55% | +117.74% | 11.48B | |
| +2.44% | +0.39% | +36.90% | +127.56% | 8.96B | |
| -1.44% | -5.02% | +18.59% | +42.70% | 7.18B | |
| -1.53% | -0.14% | +44.67% | -17.10% | 6.59B | |
| +1.52% | +1.14% | +38.17% | +247.39% | 6.45B | |
| -3.28% | -4.82% | -33.62% | -6.58% | 5.14B | |
| -18.15% | -26.80% | +57.13% | +284.24% | 3.57B | |
| Average | -2.28% | -4.78% | +21.58% | +100.91% | 14.08B | |
| Weighted average by Cap. | -1.25% | -3.24% | +20.17% | +88.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2,592B 16.17B 14.01B 12.85B 12.09B 22.52B 1,541B 22.87B 153B 59.45B 745B 60.73B 59.41B | 2,659B 16.59B 14.37B 13.18B 12.4B 23.1B 1,581B 23.46B 157B 60.98B 765B 62.29B 60.94B |
| Net income | 315B 1.96B 1.7B 1.56B 1.47B 2.74B 187B 2.78B 18.56B 7.22B 90.55B 7.38B 7.22B | 333B 2.07B 1.8B 1.65B 1.55B 2.89B 198B 2.93B 19.6B 7.63B 95.62B 7.79B 7.62B |
| Net Debt | -462B -2.88B -2.5B -2.29B -2.15B -4.01B -275B -4.08B -27.22B -10.6B -133B -10.82B -10.59B | -644B -4.02B -3.48B -3.19B -3B -5.59B -383B -5.68B -37.94B -14.77B -185B -15.08B -14.76B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-09 | 10,275.00 ¥ | -2.61% | 1,338,800 |
| 26-06-08 | 10,550.00 ¥ | -0.28% | 1,044,400 |
| 26-06-05 | 10,580.00 ¥ | -1.81% | 1,135,900 |
| 26-06-04 | 10,775.00 ¥ | -2.88% | 1,087,000 |
| 26-06-03 | 11,095.00 ¥ | -1.94% | 1,285,400 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4578 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition